1 active not recruiting, 1 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Terminated 1 |
Follow Melanoma Stage IV: new trials by email Literature Review of Melanoma Stage IV trials Research Report on Melanoma Stage IV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma BCD-217, BCD-100, Placebo - Melanoma, Melanoma (Skin) | Phase 3 | Active not recruiting | Biocad | 270 | 2022-08-02 | 2025-02-27 |
| Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence Bempegaldesleukin, Nivolumab - Melanoma, Melanoma Stage III | Phase 3 | Terminated | Nektar Therapeutics | 765 | 2020-07-27 | 2023-04-21 |
Melanoma (2) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Skin Neoplasms (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Neuroendocrine Tumors (2) · Nevi and Melanomas (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Skin Neoplasms (1)
Nivolumab (1) · bempegaldesleukin (1)
Biocad (1) · Nektar Therapeutics (1)
Russia (2) · Australia (1) · Austria (1) · Belarus (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · India (1) · Israel (1) · Italy (1) · Netherlands (1) · New Zealand (1) · Poland (1) · Portugal (1)